文献速递生殖医学

直肠给予黄体酮在个体化激素替代治疗冻融胚胎移植方案中确保高持续妊娠率:一项前瞻性干预研究

Rectal progesterone administration secures a high ongoing pregnancy rate in a personalized Hormone Replacement Therapy Frozen Embryo Transfer (HRT-FET) protocol: a prospective interventional study.
PubMed 文献 · Hum Reprod · 2023-01-01

这项前瞻性干预研究纳入488个激素替代治疗冻融胚胎移植周期,114例移植日血清黄体酮低于35 nmol/l(11 ng/ml)的患者自移植日起经直肠补充黄体酮400 mg/12 h。第12周持续妊娠率在黄体酮≥35 nmol/l组为45%、<35 nmol/l接受直肠补救组为46%,两组无显著差异(P=0.77);总流产率分别为30%与34%(P=0.53)。

要点

  • 移植日血清黄体酮低于35 nmol/l(11 ng/ml)者经直肠补充黄体酮后第12周持续妊娠率达46%。
  • 黄体酮≥35 nmol/l组与<35 nmol/l直肠补救组第12周持续妊娠率无显著差异(45% vs 46%,P=0.77)。
  • 两组总流产率无显著差异(30% vs 34%,P=0.53)。

核心结论

  • 移植日起经直肠给予黄体酮可使血清黄体酮低于35 nmol/l(11 ng/ml)的患者获得高持续妊娠率。
  • 血清黄体酮≥35 nmol/l与<35 nmol/l接受直肠补救的患者第12周持续妊娠率和总流产率均无显著差异。

研究设计与样本

  • 前瞻性干预研究,纳入2020年1月至2022年11月共488个激素替代治疗冻融胚胎移植周期。
  • 374例移植日血清黄体酮≥35 nmol/l(11 ng/ml),114例<35 nmol/l(11 ng/ml)。
  • 内膜准备为口服雌二醇6 mg/24 h,随后阴道微粒化黄体酮400 mg/12 h;黄体酮给药第6天行囊胚移植并测血清黄体酮。
  • 血清黄体酮<35 nmol/l者自当日起经直肠给予黄体酮400 mg/12 h作为补救;妊娠者直肠给药持续至妊娠第8周,雌二醇和阴道黄体酮持续至妊娠第10周。

主要发现

  • 488个单囊胚移植周期中,取卵时平均年龄30.9±4.6岁,移植时平均BMI 25.1±3.5 kg/m2。
  • 移植日阴道黄体酮后平均血清黄体酮为48.9±21.0 nmol/l(15.4±6.6 ng/ml),23%(114/488)低于35 nmol/l(11 ng/ml)。
  • 总体阳性hCG率66%(320/488)、临床妊娠率54%(265/488)、第12周持续妊娠率45%(221/488)、总流产率31%(99/320)。
  • 第12周持续妊娠率在黄体酮≥35 nmol/l组为45%、<35 nmol/l直肠补救组为46%,无显著差异(P=0.77)。
  • 总流产率在黄体酮≥35 nmol/l组为30%、<35 nmol/l直肠补救组为34%,无显著差异(P=0.53)。

临床怎么用

  • 作者认为,相当一部分接受阴道黄体酮治疗的激素替代治疗冻融胚胎移植患者血清黄体酮偏低,对这些患者加用直肠黄体酮可提高生殖结局。
  • 作者认为直肠给予黄体酮方便,黄体酮栓剂经直肠给药简单且成本低。

局限性

  • 本研究阴道及直肠使用的均为阴道微粒化黄体酮栓剂(黄体酮混悬于植物硬脂中的固体栓剂),尚不清楚其他阴道黄体酮产品(如胶囊、凝胶或片剂)经直肠使用是否具有相同的补救效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can supplementation with rectal administration of progesterone secure high ongoing pregnancy rates (OPRs) in patients with low serum progesterone (P4) on the day of blastocyst transfer (ET)? SUMMARY ANSWER: Rectally administered progesterone commencing on the ET day secures high OPRs in patients with serum P4 levels below 35 nmol/l (11 ng/ml). WHAT IS KNOWN ALREADY: Low serum P4 levels at peri-implantation in Hormone Replacement Therapy Frozen Embryo Transfer (HRT-FET) cycles impact reproductive outcomes negatively. However, studies have shown that patients with low P4 after a standard vaginal progesterone treatment can obtain live birth rates (LBRs) comparable to patients with optimal P4 levels if they receive additionalsubcutaneous progesterone, starting around the day of blastocyst transfer. In contrast, increasing vaginal progesterone supplementation in low serum P4 patients does not increase LBR. Another route of administration rarely used in ART is the rectal route, despite the fact that progesterone is well absorbed and serum P4 levels reach a maximum level after ∼2 h. STUDY DESIGN, SIZE, DURATION: This prospective interventional study included a cohort of 488 HRT-FET cycles, in which a total of 374 patients had serum P4 levels ≥35 nmol/l (11 ng/ml) at ET, and 114 patients had serum P4 levels <35 nmol/l (11 ng/ml). The study was conducted from January 2020 to November 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients underwent HRT-FET in a public Fertility Clinic, and endometrial preparation included oral oestradiol (6 mg/24 h), followed by vaginal micronized progesterone, 400 mg/12 h. Blastocyst transfer and P4 measurements were performed on the sixth day of progesterone administration. In patients with serum P4 <35 nmol/l (11 ng/ml), 'rescue' was performed by rectal administration of progesterone (400 mg/12 h) starting that same day. In pregnant patients, rectal administration continued until Week 8 of gestation, and oestradiol and vaginal progesterone treatment continued until Week 10 of gestation. MAIN RESULTS AND THE ROLE OF CHANCE: Among 488 HRT-FET single blastocyst transfers, the mean age of the patients at oocyte retrieval (OR) was 30.9 ± 4.6 years and the mean BMI at ET 25.1 ± 3.5 kg/m2. The mean serum P4 level after vaginal progesterone administration on the day of ET was 48.9 ± 21.0 nmol/l (15.4 ± 6.6 ng/ml), and a total of 23% (114/488) of the patients had a serum P4 level lower than 35 nmol/l (11 ng/ml). The overall, positive hCG rate, clinical pregnancy rate, OPR week 12, and total pregnancy loss rate were 66% (320/488), 54% (265/488), 45% (221/488), and 31% (99/320), respectively. There was no significant difference in either OPR week 12 or total pregnancy loss rate between patients with P4 ≥35 nmol/l (11 ng/ml) and patients with P4 <35 nmol/l, who received rescue in terms of rectally administered progesterone, 45% versus 46%, P = 0.77 and 30% versus 34%, P = 0.53, respectively. OPR did not differ whether patients had initially low P4 and rectal rescue or were above the P4 cut-off. Logistic regression analysis showed that only age at OR and blastocyst scoring correlated with OPR week 12, independently of other factors like BMI and vitrification day of blastocysts (Day 5 or 6). LIMITATIONS, REASONS FOR CAUTION: In this study, vaginal micronized progesterone pessaries, a solid pessary with progesterone suspended in vegetable hard fat, were used vaginally as well as rectally. It is unknown whether other vaginal progesterone products, such as capsules, gel, or tablet, could be used rectally with the same rescue effect. WIDER IMPLICATIONS OF THE FINDINGS: A substantial part of HRT-FET patients receiving vaginal progesterone treatment has lowserum P4. Adding rectally administered progesterone in these patients increases the reproductive outcome. Importantly, rectal progesterone administration is considered convenient, and progesterone pessaries are easy to administer rectally and of low cost. STUDY FUNDING/COMPETING INTEREST(S): Gedeon Richter Nordic supported the study with an unrestricted grant as well as study medication. B.A. has received unrestricted grant from Gedeon Richter Nordic and Merck and honoraria for lectures from Gedeon Richter, Merck, IBSA and Marckyrl Pharma. P.H. has received honoraria for lectures from Gedeon Richter, Merck, IBSA and U.S.K. has received grant from Gedeon Richter Nordic, IBSA and Merck for studies outside this work and honoraria for teaching from Merck and Thillotts Pharma AB and conference expenses covered by Merck. The other co-authors have no conflict of interest to declare. TRIAL REGISTRATION NUMBER (25): EudraCT no.: 2019-001539-29.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Alsbjerg B, Jensen MB, Povlsen BB, et al. Rectal progesterone administration secures a high ongoing pregnancy rate in a personalized Hormone Replacement Therapy Frozen Embryo Transfer (HRT-FET) protocol: a prospective interventional study. Hum Reprod. 2023. PMID: 37759346. doi:10.1093/humrep/dead185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。